Approval · Notice of Compliance 36866 · 2026
NAT-POMALIDOMIDE: Notice of Compliance 36866
Issued February 9, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36866
- Date
- February 9, 2026
- Company
- Natco Pharma (Canada) IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to Product Monograph (to align with CRP approved PM)
- Canadian reference product
- POMALYST (Celgene Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NAT-POMALIDOMIDE | Not yet assigned | — |
Medicinal ingredients
- POMALIDOMIDE 1 MG per CAP
- POMALIDOMIDE 2 MG per CAP
- POMALIDOMIDE 3 MG per CAP
- POMALIDOMIDE 4 MG per CAP